New treatment options for lower respiratory tract infections (Q40111519)

17 September 2017

title

New treatment options for lower respiratory tract infections (English)

1 reference

respiratory tract infection

17 September 2017

main subject

1 reference

Bela Kocsis

1 reference

17 September 2017

Dora Szabo

series ordinal

1 reference

17 September 2017

language of work or name

English

0 references

publication date

1 August 2017

1 reference

Expert Opinion on Pharmacotherapy

17 September 2017

published in

1 reference

17 September 2017

1 reference

17 September 2017

1 reference

17 September 2017

page(s)

1345-1355

1 reference

Pathogenesis of lower respiratory tract infections due to Chlamydia, Mycoplasma, Legionella and viruses

17 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

The state of US health, 1990-2010: burden of diseases, injuries, and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Lifetime risk of COPD: what will the future bring?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Prediction and course of symptoms and lung function around an exacerbation in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. The EOLO Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Chronic bronchitis and chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Risk factors and early origins of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

I have taken my umbrella, so of course it does not rain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Infectious etiology of acute exacerbations of chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Community-acquired pneumonia in elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Hospitalized community-acquired pneumonia in the elderly: age- and sex-related patterns of care and outcome in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Infections with Viruses and Mycoplasma pneumoniae during Exacerbations of Chronic Bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Aerodynamic size distribution of cromolyn sodium at ambient and airway humidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

The role of solithromycin in the management of bacterial community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

A review of guidelines for antibacterial use in acute exacerbations of chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

High Prevalence and Resistance Patterns of Community-Associated Methicillin-Resistant Staphylococcus Aureus in the Pomoravlje Region, Serbia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Chemistry and mode of action of macrolides

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

The ketolides: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Review of macrolides and ketolides: focus on respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Telithromycin-associated hepatotoxicity: Clinical spectrum and causality assessment of 42 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Results from the Solithromycin International Surveillance Program (2014).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Molecular Characterization of Off-Target Activities of Telithromycin: a Potential Role for Nicotinic Acetylcholine Receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

The solithromycin journey-It is all in the chemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Binding and action of CEM-101, a new fluoroketolide antibiotic that inhibits protein synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Renaissance of antibiotics against difficult infections: Focus on oritavancin and new ketolides and quinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Macrolide antibiotics in the ribosome exit tunnel: species-specific binding and action

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

In vitro and in vivo antibacterial activities of DW-224a, a new fluoronaphthyridone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

In vitro spectrum of activity of finafloxacin, a novel, pH-activated fluoroquinolone, under standard and acidic conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Solithromycin inhibition of protein synthesis and ribosome biogenesis in Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenzae

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Comparison of plasma, epithelial lining fluid, and alveolar macrophage concentrations of solithromycin (CEM-101) in healthy adult subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

A novel macrolide solithromycin exerts superior anti-inflammatory effect via NF-κB inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

A novel macrolide/fluoroketolide, solithromycin (CEM-101), reverses corticosteroid insensitivity via phosphoinositide 3-kinase pathway inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Application of fluoroquinolone pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Single and Multiple Ascending-dose Studies of Oral Delafloxacin: Effects of Food, Sex, and Age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Comparison of pharmacokinetics between new quinolone antibiotics: the zabofloxacin hydrochloride capsule and the zabofloxacin aspartate tablet

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Pharmacokinetics of Solithromycin (CEM-101) after Single or Multiple Oral Doses and Effects of Food on Single-Dose Bioavailability in Healthy Adult Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Safety and Pharmacokinetics of Solithromycin in Subjects with Hepatic Impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Prospects for new antibiotics: a molecule-centered perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Quinolones in 2005: an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Plasmid-mediated quinolone resistance: Two decades on.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Zabofloxacin for chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Subacute toxicity and toxicokinetics of a new antibiotic, DW-224a, after single and 4-week repeated oral administration in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Zabofloxacin versus moxifloxacin in patients with COPD exacerbation: a multicenter, double-blind, double-dummy, randomized, controlled, Phase III, non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Contrasting Effects of Acidic pH on the Extracellular and Intracellular Activities of the Anti-Gram-Positive Fluoroquinolones Moxifloxacin and Delafloxacin againstStaphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Delafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

In vitro activities of ABT-492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

The in vitro activity of a new fluoroquinolone, ABT-492, against recent clinical isolates of Chlamydia pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Comparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ureaplasmas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

In Vitro Antibacterial Potency and Spectrum of ABT-492, a New Fluoroquinolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

A combined pharmacodynamic quantitative and qualitative model reveals the potent activity of daptomycin and delafloxacin against Staphylococcus aureus biofilms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Comparison of the antibiotic activities of Daptomycin, Vancomycin, and the investigational Fluoroquinolone Delafloxacin against biofilms from Staphylococcus aureus clinical isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Characterisation of COPD heterogeneity in the ECLIPSE cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Increased susceptibility of Pseudomonas aeruginosa to macrolides and ketolides in eukaryotic cell culture media and biological fluids due to decreased expression of oprM and increased outer-membrane permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1363179

10.1080/14656566.2017.1363179

21 January 2018

Identifiers

DOI

1 reference

17 September 2017

1 reference